All Releases
 |
Optimer Pharmaceuticals Submits Fidaxomicin Marketing Authorization Application for the Treatment of Clostridium difficile Infection
Jul 29, 2010
|
12.8 KB |
| |
SAN DIEGO, July 29, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it has submitted a Marketing Authorization Application (MAA) for fidaxomicin to the European Medicines Agency (EMA) under the European Union's Centralized Procedure. Optimer is seeking approval to market fidaxomicin for...
|
|
Optimer Pharmaceuticals to Present at August 2010 Investor Conferences
Jul 28, 2010
|
9.1 KB |
| |
SAN DIEGO, July 28, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:
30th Annual Canaccord Genuity Growth Conference on Thursday, August 12, 2010 at 2:00 p.m. Eastern Time at the InterContinental Boston. A live audio webca...
|
|
Optimer Pharmaceuticals Receives Milestone Payment From Cempra for Next-Generation Macrolide Antibiotic
Jul 8, 2010
|
11.3 KB |
| |
SAN DIEGO, July 8, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced it has received a $500,000 milestone payment from Cempra Pharmaceuticals, Inc. pursuant to the terms of a licensing agreement between the companies. The milestone payment was made as a result of Cempra's continuing developm...
|
|
Optimer Pharmaceuticals to Present at June 2010 Investor Conferences
Jun 1, 2010
|
9.2 KB |
| |
SAN DIEGO, June 1, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:
Jefferies 2010 Global Life Sciences Conference on Wednesday, June 9, 2010 at 9:30 a.m. Eastern Time at The Grand Hyatt in New York City.9th Annual Needham ...
|
|
Optimer Pharmaceuticals and Biocon Limited Announce Manufacturing and Supply Agreement for Fidaxomicin
May 24, 2010
|
12.5 KB |
| |
SAN DIEGO and BANGALORE, India, May 24, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) a biopharmaceutical company focused on the treatment of serious infections such as Clostridium difficile infection (CDI), and Biocon Limited (NSE: BIOCON), one of India's premier biotechnology companies and a global prov...
|
|
Optimer Pharmaceuticals Reports First Quarter 2010 Financial Results
May 6, 2010
|
13.5 KB |
| |
SAN DIEGO, May 6, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced its financial results for the quarter ended March 31, 2010.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
Optimer reported a net loss for the first quarter of 2010 of $13.5 million, or $0.39 per share whi...
|
|
Optimer Pharmaceuticals Appoints Pedro Lichtinger as President and CEO to Succeed Michael N. Chang, Ph.D., Who Will Serve as Chairman of the Board
May 6, 2010
|
11.3 KB |
| |
SAN DIEGO, May 6, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that Pedro Lichtinger has been appointed President and Chief Executive Officer of the Company as well as to the Board of Directors. Pedro Lichtinger joins Optimer with more than 30 years of global business experience in the p...
|
|
Data From Optimer's Second Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) Featured in Oral Presentation at Digestive Disease Week
May 4, 2010
|
12.9 KB |
| |
SAN DIEGO, May 4, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced the presentation of new data from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection (CDI). The data, presented by Stuart Johnson, M.D. during an oral session at the annual meeting of Dig...
|
|
Optimer Pharmaceuticals Announces Oral Presentation at Digestive Disease Week (DDW) Featuring Data From the Second Fidaxomicin Phase 3 Trial
Apr 22, 2010
|
8.5 KB |
| |
SAN DIEGO, April 22, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data from the second fidaxomicin Phase 3 clinical study will be presented in an oral presentation at Digestive Disease Week (DDW) 2010 in New Orleans.
"Randomized Clinical Trial (RCT) in Clostridium difficile Infe...
|
|
Positive Results from Optimer Pharmaceuticals' Second Phase 3 Study of Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) Presented at ECCMID
Apr 10, 2010
|
15.8 KB |
| |
SAN DIEGO, April 10, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that the top-line results from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection (CDI) were presented today at the 20th Annual European Congress of Clinical Microbiology and Infectious...
|
|
Optimer Pharmaceuticals Announces Presentations of Data From the Fidaxomicin Phase 3 Trials at ECCMID
Apr 6, 2010
|
9.0 KB |
| |
SAN DIEGO, April 6, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data from the fidaxomicin Phase 3 clinical studies will be presented at the 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria.
(Logo: http://www.newscom.com/cgi-bin/p...
|
|
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Financial Results
Mar 11, 2010
|
17.8 KB |
| |
SAN DIEGO, March 11, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced 2009 fourth quarter and full year financial results and accomplishments.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
Optimer reported a net loss for the three months ended December 31, 2009 of $9.6 m...
|
|
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2009 Financial Results
Mar 3, 2010
|
9.1 KB |
| |
SAN DIEGO, March 3, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced it expects to report fourth quarter and full year 2009 financial results after the NASDAQ Global Market closes on Thursday, March 11, 2010. The Company also expects to host a conference call that day at 4:30 p.m. Eastern Ti...
|
|
Optimer Pharmaceuticals, Inc. Announces Completion of Public Offering of Common Stock
Mar 1, 2010
|
7.8 KB |
| |
SAN DIEGO, March 1, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the closing of its previously announced public offering of 4,887,500 shares of its common stock, including 637,500 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriter. ...
|
|
Optimer Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
Mar 1, 2010
|
8.7 KB |
| |
SAN DIEGO, March 1, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at the Cowen and Company 30th Annual Health Care Conference at The Boston Marriott Copley Place on March 8, 2010, 4:00 p.m. Eastern Time.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
A live aud...
|
|
Optimer Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
Feb 24, 2010
|
8.8 KB |
| |
SAN DIEGO, Feb 24, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the pricing of a public offering of 4,250,000 shares of its common stock. The offering is expected to close on or about March 1, 2010, subject to customary closing conditions. In addition, Optimer has granted the underwriter ...
|
|
Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Clostridium Difficile Infection
Feb 4, 2010
|
17.1 KB |
| |
SAN DIEGO, Feb 04, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced positive top-line results from the second of two pivotal Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI). This study was conducted in approxim...
|
|
Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
Dec 16, 2009
|
8.7 KB |
| |
SAN DIEGO, Dec 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at the 28th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 13, 2010. Michael N. Chang, Optimer's President and Chief Executive Officer, will p...
|
|
Optimer Pharmaceuticals Appoints Robert L. Zerbe, M.D. to its Board of Directors
Dec 3, 2009
|
10.3 KB |
| |
SAN DIEGO, Dec 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announcedthat Robert L. Zerbe, M.D., has joined the company's Board of Directors and will be an active member of the company's compensation committee. Dr. Zerbe brings to the Board more than 25 years of pharmaceutical developm...
|
|
Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
Nov 24, 2009
|
8.6 KB |
| |
SAN DIEGO, Nov 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at the 21st Annual Piper Jaffray Health Care Conference at The New York Palace in New York City on December 1, 2009 at 1:00 p.m. Eastern Time.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO...
|
|
|
